A glucagon-GLP-1 dual agonist cleared its liver-fat endpoint in a 216-person phase 3

Survodutide is a dual agonist: it activates the glucagon receptor as well as the GLP-1 receptor. The glucagon arm is the part that makes it interesting for the liver specifically, and SYNCHRONIZE-MASLD is the phase 3 trial built to test that.

The results, published in Nature Medicine on June 7, are positive on both co-primary endpoints and narrower than the headline number suggests [s1].

The trial

SYNCHRONIZE-MASLD randomised 216 adults — 131 female and 85 male — with obesity and at-risk metabolic dysfunction-associated steatotic liver disease [s1]. Obesity was defined as a body mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one obesity complication [s1]. At-risk MASLD was defined by evidence of liver inflammation or fibrosis on non-invasive tests, or biopsy-confirmed steatohepatitis [s1].

Participants were randomised 2:1 to once-weekly subcutaneous survodutide 6.0 mg (n = 146) or placebo (n = 70), for 48 weeks [s1].

The two co-primary endpoints were a 30% or greater reduction in liver fat content measured by MRI proton density fat fraction, and percentage change in body weight, both from baseline to week 48 [s1].

What it found

Both endpoints were met [s1].

On liver fat, 84.2% of survodutide patients versus 24.3% of placebo patients achieved a 30% or greater reduction using the efficacy estimand (P < 0.0001) [s1]. Under the treatment regimen estimand — the more conservative analysis, which counts people regardless of whether they stayed on drug — the figures were 68.5% versus 28.6% (P < 0.0001) [s1].

On weight, mean change was −12.2% with survodutide against −1.0% with placebo on the efficacy estimand, and −8.7% against −1.4% on the treatment regimen estimand (both P < 0.0001) [s1].

The gap between the two estimands is worth sitting with. It is the arithmetic of people stopping the drug, and it is roughly a quarter of the weight effect.

The most frequent adverse events were gastrointestinal, occurred mainly during dose escalation, and were generally mild to moderate [s1] — the pattern this drug class has produced consistently.

The endpoint that was not measured

Liver fat on MRI is a surrogate. What determines whether someone with MASLD develops cirrhosis or liver cancer is fibrosis, and fibrosis is assessed on biopsy. SYNCHRONIZE-MASLD did not report a histological fibrosis endpoint.

This distinction is not academic, and the field has a recent example of why. An updated meta-analysis of semaglutide in MASLD and steatohepatitis, published on June 11, pooled ten studies covering 1,908 patients [s2]. Semaglutide significantly improved resolution of steatohepatitis without worsening fibrosis (odds ratio 3.48; 95% CI 2.68–4.53; P < 0.00001) [s2]. But pooled fibrosis improvement of at least one stage was not statistically significant (odds ratio 1.17; 95% CI 0.49–2.80; P = 0.72) [s2].

The same analysis found semaglutide reduced liver stiffness by 1.25 kPa (95% CI −2.18 to −0.32; P = 0.009) and raised the odds of a 30% or greater relative reduction in liver fat sevenfold (odds ratio 7.16; 95% CI 3.08–16.64) [s2], alongside a higher risk of gastrointestinal adverse events (risk ratio 1.83; 95% CI 1.20–2.79) [s2].

So the pattern across this drug class so far is: liver fat moves a lot, inflammation resolves, and fibrosis is the endpoint that has not clearly followed.

Limits the authors state

The trial ran 48 weeks — short for a disease measured in decades — and recruited only in the United States and Spain, which the authors name as a limit on global reach [s1]. With 216 participants, subgroup questions are underpowered by construction.

Survodutide is described in the paper as under investigation [s1]. Nothing here is an approval, and nothing here says how the drug compares head-to-head with the GLP-1 agents already in use for this indication.

What to watch

Two things. Whether a longer trial with histology attached shows fibrosis moving, and whether the glucagon component — the mechanistic reason to expect a liver-specific benefit beyond weight loss — turns out to add anything once weight change is accounted for. Neither question is answered by a 48-week fat-fraction endpoint.

This article is informational and is not medical advice. Decisions about any of these medications belong with a clinician who knows the individual case.

Sources

• Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial — Nature Medicine, 2026-06-07
• Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis — British Journal of Clinical Pharmacology, 2026-06-11